Vertex Pharmaceuticals Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for VRTX, updated each market day.
VRTX AI Sentiment
AI sees no strong directional signal for Vertex Pharmaceuticals Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Sector
Exchange
Market Cap
$113,642,842,403
Cap Tier
Employees
6,400
Headquarters
BOSTON, MA
Listed Since
July 31, 1991
Website
VRTX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
VRTX Volatility
Vertex Pharmaceuticals Inc has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
